HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target

Benzinga · 5d ago
HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.